ATE511519T1 - ANTIBODY FRAGMENT AS A MULTIDRUG RESISTANCE MODULATOR AND COMPOSITIONS, KITS AND METHODS THEREOF - Google Patents

ANTIBODY FRAGMENT AS A MULTIDRUG RESISTANCE MODULATOR AND COMPOSITIONS, KITS AND METHODS THEREOF

Info

Publication number
ATE511519T1
ATE511519T1 AT04700749T AT04700749T ATE511519T1 AT E511519 T1 ATE511519 T1 AT E511519T1 AT 04700749 T AT04700749 T AT 04700749T AT 04700749 T AT04700749 T AT 04700749T AT E511519 T1 ATE511519 T1 AT E511519T1
Authority
AT
Austria
Prior art keywords
antibody fragment
methods
kits
compositions
multidrug resistance
Prior art date
Application number
AT04700749T
Other languages
German (de)
Inventor
Yoram Reiter
Maya Haus-Cohen
Original Assignee
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Res & Dev Foundation filed Critical Technion Res & Dev Foundation
Application granted granted Critical
Publication of ATE511519T1 publication Critical patent/ATE511519T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

An antibody fragment and methods of utilizing same are provided. The antibody fragment includes an antigen binding region capable of binding an extracellular portion of a P-glycoprotein thereby at least partially inhibiting drug efflux activity in multidrug resistant cells.
AT04700749T 2003-04-02 2004-01-08 ANTIBODY FRAGMENT AS A MULTIDRUG RESISTANCE MODULATOR AND COMPOSITIONS, KITS AND METHODS THEREOF ATE511519T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/405,123 US7294701B2 (en) 2003-04-02 2003-04-02 Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
PCT/IL2004/000017 WO2004087041A2 (en) 2003-04-02 2004-01-08 An antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same

Publications (1)

Publication Number Publication Date
ATE511519T1 true ATE511519T1 (en) 2011-06-15

Family

ID=33097024

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04700749T ATE511519T1 (en) 2003-04-02 2004-01-08 ANTIBODY FRAGMENT AS A MULTIDRUG RESISTANCE MODULATOR AND COMPOSITIONS, KITS AND METHODS THEREOF

Country Status (8)

Country Link
US (1) US7294701B2 (en)
EP (1) EP1608307B1 (en)
JP (1) JP4576375B2 (en)
AT (1) ATE511519T1 (en)
CA (1) CA2520936C (en)
ES (1) ES2364462T3 (en)
HK (1) HK1085664A1 (en)
WO (1) WO2004087041A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059143A2 (en) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof
US8835608B2 (en) * 2006-12-01 2014-09-16 Duke University Anti-MRP3 antibodies and methods of use
WO2017013172A1 (en) * 2015-07-23 2017-01-26 Stichting Katholieke Universiteit Novel inhibitors of p-glycoprotein

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US3879517A (en) 1972-12-26 1975-04-22 Microdot Inc Method for making a dual seal insulator for multiple conductor connectors
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4837306A (en) 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5773280A (en) * 1992-03-20 1998-06-30 The Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
US5434075A (en) * 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
DE69233367T2 (en) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla LIBRARIES OF HETERODIMERIC RECEPTORS BY PHAGEMIDES
US5407653A (en) 1991-06-26 1995-04-18 Brigham And Women's Hospital Evaluation of the multidrug resistance phenotype
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
IT1257893B (en) 1992-06-17 1996-02-16 Ist Superiore Sanita MONOCLONAL ANTIBODIES THAT RECOGNIZE AN EPITOPE OF HUMAN P-GLYCOPROTEIN.
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CZ199593A3 (en) 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
EP0669941A1 (en) * 1992-11-02 1995-09-06 NICOLAU, Yves Claude Method of reducing multidrug resistance in cells and tissues
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5543423A (en) 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
AU3482297A (en) * 1996-06-05 1998-01-05 Eugene Mechetner Reagents and methods for inhibiting cytokine release by blood cells

Also Published As

Publication number Publication date
ES2364462T3 (en) 2011-09-02
CA2520936C (en) 2013-06-11
EP1608307A2 (en) 2005-12-28
US20040197334A1 (en) 2004-10-07
JP4576375B2 (en) 2010-11-04
JP2006524505A (en) 2006-11-02
EP1608307A4 (en) 2007-10-31
WO2004087041A2 (en) 2004-10-14
HK1085664A1 (en) 2006-09-01
EP1608307B1 (en) 2011-06-01
WO2004087041A3 (en) 2005-11-17
US7294701B2 (en) 2007-11-13
CA2520936A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
BRPI0506777A (en) muscarinic acetylcholine receptor antagonists
BRPI0415361A (en) muscarinic acetylcholine receptor antagonists
DK1773885T3 (en) Humanized anti-c-met antagonists
CY2017009I1 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
CY1117124T1 (en) HUMANIZED ANTI-β7 ANTAGONISTS AND THEIR USES
BRPI0510170A (en) muscarinic acetylcholine receptor antagonists
NO20076003L (en) TGF-beta 1 specific antibodies
CU23809A3 (en) PRLR SPECIFIC ANTIBODY
ECSP077310A (en) ANTI-5T4 HUMANIZED AND CONJUGATED ANTIBODIES ANTI-5T4 / CALIQUEAMYCIN ANTIBODIES
PT1546734E (en) N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
NO20060776L (en) Muscarine acetylcholine receptor antagonists
WO2006039470A9 (en) Anti- amyloid antibodies, compositions, methods and uses
UY28598A1 (en) MUSCARINIC ACETILCOLINE RECEIVERS ANTAGONISTS
NL1023801A1 (en) Method for setting the Wobbe index of a fuel and compositions thereof.
SG170793A1 (en) Anti-mn antibodies and methods of using same
ATE477275T1 (en) ANTIBODIES AGAINST CD28
WO2005107491A3 (en) Multi-lectin affinity chromatography and uses thereof
WO2005068503A3 (en) M-csf-specific monoclonal antibody and uses thereof
ATE501731T1 (en) MELANOCORTIN RECEPTOR-BINDING MIMETIBODIES, COMPOSITIONS, METHODS AND USES
EA200701766A1 (en) ANTIBODIES AGAINST CANDIDA ANTIGENS
CY1114497T1 (en) METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF INTEGRITY
ATE517340T1 (en) SETS OF DIGITAL ANTIBODIES DIRECTED AGAINST SHORT EPITOPES AND METHODS USING THEM
BRPI0415281A (en) muscarinic acetylcholine receptor antagonists
HK1085664A1 (en) An antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
WO2007092664A3 (en) Blocker reagent for reduction of heterophile interferences

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties